Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 1, 2016, Pages 26-30

  Stetler Stevenson, Maryalice ^a   Paiva, Bruno ^b   Stoolman, Lloyd ^c   Lin, Pei ^d   Jorgensen, Jeffrey L ^d   Orfao, Alberto ^e   Van Dongen, Jacques ^f   Rawstron, Andy C ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CSIC   (Spain)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g James's Institute of Oncology   (United Kingdom)

Author keywords

flow cytometry; minimal residual disease; myeloma

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN;

ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER PROGNOSIS; CONSENSUS DEVELOPMENT; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; GOOD CLINICAL PRACTICE; HUMAN; INFORMATION PROCESSING; MEDICAL DOCUMENTATION; MINIMAL RESIDUAL DISEASE; MYELOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; STAINING; STANDARDIZATION; TREATMENT RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; MEASUREMENT ACCURACY; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PATHOLOGY; PLASMA CELL; PRACTICE GUIDELINE; PROGNOSIS; REMISSION; SPECIMEN HANDLING; STANDARDS;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; DATA ACCURACY; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PLASMA CELLS; PROGNOSIS; REMISSION INDUCTION; SPECIMEN HANDLING; STAINING AND LABELING;

EID: 84935090392     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21249     Document Type: Article

References (23)

1. van Dongen JJM, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–1975.
2. Rawstron AC, Orfao A, Beksac M, et al. Report of the European myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematol-Hematol J 2008;93:431–438.
3. Davis BH, Wood B, Oldaker T, Barnett D. Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part I - rationale and aims. Cytometry B Clin Cytom 2013;84:282–285.
4. Wood B, Jevremovic D, Bene MC, Yan M, Jacobs P, Litwin V, and on behalf of ICSH/ICCS Working Group Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom 2013;84:315–323.
5. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312–328.
6. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V. Recommendations for the validation of flow cytometric testing during drug development: II Assays. J Immunol Methods 2011;363:120–134.
7. Stetler-Stevenson M, Ahmad, E, Barnett, D, Braylan, RC, DiGiuseppe, JA, Marti, G, Menozzi, D,Oldaker, TA, Orfao A, Rabellino, E, Stone, EC, Walker, C. Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline-Second Edition. CLSI document H43-A2. Wayne, Pennsylvania, 19087-1898. USA: Clinical and Laboratory Standards Institute; 2005.
8. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26:1986–2010.
9. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: Major heterogeneity. Blood 2013;122:1088–1089.
10. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Greipp PR, Rajkumar SV. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106:2276–2279.
11. Dingli D, Nowakowski GS, Dispenzieri A, Tracz MJ, Greipp PR, Rajkumar SV. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: A simple risk stratification system. Blood 2006;107:3384
12. Barnett DSI, Wilson GA, Granger V, Reilly JT. Determination of leucocyte antibody binding capacity (ABC): The need for standardization. Clin Lab Haematol 1998;20:155–164.
13. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–2744.
14. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol 1997;97:46–55.
15. Le Roy C, Varin-Blank N, Ajchenbaum-Cymbalista F, Letestu R. Flow cytometry APC-tandem dyes are degraded through a Cell-dependent mechanism. Cytometry Part A 2009;75A:882–890.
16. Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne A, Yuan CM, Marti GE, Stetler-Stevenson M. Variables affecting the quantitation of cd22 in neoplastic B cells. Cytometry Part B 2011;80:83–90.
17. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007;21:2043–2046.
18. Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G, Preffer F. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry Part B: Clin Cytometry 2010;78:231–238.
19. Liu DS, Lin P, Hu Y, Zhou Y, Tang GL, Powers L, Medeiros LJ, Jorgensen JL, Wang SA. Immunophenotypic heterogeneity of normal plasma cells: Comparison with minimal residual plasma cell myeloma. J Clin Pathol 2012;65:823–829
20. Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 2014;38:371–376.
21. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J, Borrego D, Rodriguez MJ, Ortega F, Hernandez J, Moreno I, Dominguez M, Mateo G, San Miguel JF, Orfao A. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19:449–455.
22. Harada H, Kawano MM, Huang N, Iwato Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658–2663.
23. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482–488.